Restriction Endonucleases Products Market Size by Application, End User, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2029
Overview
Global Restriction Endonucleases Products Market size was valued at US$ 370 Mn in 2022 and the total revenue is expected to grow at 5.5% through 2022 to 2029, reaching nearly US$ 538.24 Mn in the forecast period.
Global Restriction Endonucleases Products Market Overview:
Restriction endonucleases are also known as the restriction enzyme. Restriction Endonucleases is a process included in the reaction mixture that cuts the unmodified DNA strand at a Double-stranded hemiphophorothioate recognition site, which occurs when the 5’-[a-thio] triphosphate nucleotide is incorporated. 
To know about the Research Methodology :- Request Free Sample Report
Global Restriction Endonucleases Products Market Dynamics:
Restriction Endonucleases product market is greatly driven by increase research studies on life science, genomics, and growing no. of geriatric population with a high prevalence of chronic disease, cardiovascular diseases, cancer, and diabetes. Moreover, biotechnology is likely to fuel the growth of the market like DNA sequencing and gene expression, by which nucleotides are extracted. Further, this process is likely to create more demand in the market. As the healthcare industry is growing at a rapid pace and demand for molecular biology enzymes, kits and reagents are anticipated to gain more attention.
The application of restriction endonucleases products is gaining huge attention in the market for conventional cloning, building DNA libraries, gene editing in - vivo environments, molecular biology techniques. Moreover, rising application and usage is likely to create more opportunities for the market players to invest in the restriction endonucleases product manufacturing.
In addition, the high cost of the gene therapy and restriction endonucleases process is likely to hinder the growth concerning the development of restriction endonucleases production downstream activities together with the extent of undependability of restriction enzymes product in delivering the results.
Global Restriction Endonucleases Products Market Segment Analysis:
PCR Application segment is dominating the Application segment of Global Restriction Endonucleases Products Market:
The polymerase Chain Reaction (PCR) segment gained the largest market share in 2019 and is likely to grow further in the forecast period. This method is used to generate tens of billions of copies of particular DNA fragments. Polymerase Chain Reaction (PCR) is generally a technique of purification or cloning. DNA is extracted from an organism or sample containing DNA of various origins which is not analyzed directly.
The global polymerase Chain Reaction (PCR) market was valued at 4500 million in 2019 and is expected to proliferate at a CAGR of 17.5% in the forecast period. The major factor driving the growth of the market is demand for advanced technology, rising contract manufacturing organization (CRO), and forensic and research laboratories due to the precise handling, automation, real-time quantification, and sensitivity. Moreover, rising government initiatives for improving research activity are likely to boost the growth of the market.
For instance, in 2018, the market player of Northwestern Europe, Genomics Medicine Ireland (GMI) received funding from the government of USD 413.91 million for conducting genomic research in Ireland.
Moreover, the launching of new technologies is likely to strengthen their product portfolio and sustain them in the market. For instance, in 2019, Thermo Fisher Scientific, Inc. company launched the world’s first smart qPCR instrument. The capabilities of the instrument include, facial authentication, voice command, radio-frequency Identification (RFID)-enabled plate scanning, with quick access to service and support with a single touch.
The Pharmaceutical Industry segment is considered to supplement the growth of the Global Restriction Endonucleases Products Market.
Pharmaceutical and biotechnology companies dominated the end-user segment of the Restriction Endonucleases Products market with 12.8% of market share and are expected to grow at a high pace during the forecast period. Supplementary, the investment by the pharmaceutical companies in R&D for gene therapies and Restriction Endonucleases Products applications is likely to lift the growth of the market.
In 2019, the global expenditure on research and development by pharmaceutical industries was around 190 billion. The growth of the segment is strongly driven by the manufacturing of innovative products by aiding research and development activities. Additionally, patents registered by individuals or companies are boosting the Restriction Endonucleases Products market. Further, demand for Contract Research Organizations (CRO) and Contract Manufacturing Organizations (CMO) are likely to fuel the growth of the market. Moreover, Contract Research Organizations is likely to reach USD 106 billion by the end of 2029, with a CAGR of 10.7%.
Global Restriction Endonucleases Products Market Regional Insights:
Global Restriction Endonucleases Products Market Regional Insights is segmented into North America, Asia Pacific, Europe, Latin America, Middle East, and Africa.
North America is leading in the Restriction Endonucleases Products Market with 41.7% of market share in 2022 due to the presence of a prominent market player like Agilent Technologies. The growth of the region is attributed to the broader acceptance of technologies and development in research activities with high-end infrastructure. Moreover, mergers and acquisitions are playing an important role in the Restriction Endonucleases Products market.
These mergers and acquisitions by the top market players are likely to stimulate the growth of the market due to the forecast period. For example, in 2019, Agilent company acquired Biotech Instruments for 1.165 billion. The Agilent company further acquired ACEA Bioscience for worth USD 250 million to sustain in the market and strengthen their position in the market.
Asia Pacific is gaining a significant market share with the highest CAGR of 7.8% during the forecast period. As biotechnology and pharmaceutical companies are responsible powerful the growth of the market. Moreover, the growth of the region is by amplified biotechnological activities carried out by private or government research organizations for innovative biologics. Besides growing consumer awareness regarding development in technologies is likely to lift the market expansion.
The objective of the report is to present a comprehensive analysis of the Global Restriction Endonucleases Products Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the Global Restriction Endonucleases Products Market dynamics, structure by analyzing the market segments and project the Global Restriction Endonucleases Products Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global Restriction Endonucleases Products Market make the report investor’s guide.
Global Restriction Endonucleases Products Market Scope: Inquire before buying
| Global Restriction Endonucleases Products Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 370 Mn. |
| Forecast Period 2023 to 2029 CAGR: | 5.5% | Market Size in 2029: | US $ 538.24 Mn. |
| Segments Covered: | by Application | PCR (Polymerase Chain Reaction) Epigenetics Restriction Fragment Length Polymorphism (RFLP) Cloning Sequencing Restriction Digestion |
|
| by End User | Hospitals Academic Research Institutes Pharmaceutical and Biotechnology Companies Diagnostic Centers Clinics Other |
||
Global Restriction Endonucleases Products Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Global Restriction Endonucleases Products Market Key Player
1. Agilent Technologies, Inc.
2. Thermo Fisher Scientific Inc.
3. Affymetrix, Inc.
4. Illumina, Inc.
5. Enzymatics, Inc.
6. QIAGEN N.V.
7. New England Biolabs, Inc.
8. Sigma-Aldrich Co. LLC.
9. Roche, Ltd.
10.Takara Bio, Inc
FAQs:
1. What is the global Restriction Endonucleases Products Market share in 2022?
Ans: Approximately, 370 Million USD.
2. What is the global Restriction Endonucleases Products Market growth?
Ans: The global Restriction Endonucleases Products Market is anticipated to grow with a CAGR of 5.5% in the forecast period and is likely to reach USD 538 million by the end of 2029.
3. Which Application segment is expected to dominate the global Restriction Endonucleases Products Market during the forecast period?
Ans: The PCR (Polymerase Chain Reaction) segment dominated the market with a share of over 38.4% in 2022 and is expected to exhibit the highest CAGR of 17.5% during the forecast period.
4. Which region is expected to dominate the global Restriction Endonucleases Products Market during the forecast period?
Ans: North America dominated the Restriction Endonucleases Products Market with a share of over 41.7% in 2022. The growth of the region is attributed to the broader acceptance of technologies and development in research activities with high-end infrastructure.
5. Who are the key players in the global Restriction Endonucleases Products Market?
Ans: Key players of the market include Agilent Technologies, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Merck Millipore, QIAGEN, Clontech Laboratories, Inc., DNA2.0, New England Biolabs, Sigma-Aldrich Corporation, and GenScript USA Inc